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Abstract
Background and Aims: We assessed the clinical and economic impact of direct- acting 
antiviral (DAA) therapy for hepatitis C virus (HCV) in England, Italy, Romania and Spain.
Methods: An HCV progression Markov model was developed considering DAA eligi-
bility and population data during the years 2015- 2019. The period of time to recover 
the investment in DAAs was calculated as the cost saved by avoiding estimated clini-
cal events for 1000 standardized treated patients. A delayed treatment scenario be-
cause of coronavirus disease (COVID- 19) was also developed.
Results: The estimated number of avoided hepatocellular carcinoma, decompensated 
cirrhosis and liver transplantations over a 20- year time horizon was: 1,057 in England; 
1,221 in Italy; 1,211 in Romania; and 1,103 in Spain for patients treated during 2015- 
2016 and 640 in England; 626 in Italy; 739 in Romania; and 643 in Spain for patients 
treated during 2017- 2019. The cost- savings ranged from € 45 to € 275 million. The 
investment needed to expand access to DAAs in 2015- 2019 is estimated to be re-
covered in 6.5 years in England; 5.4 years in Italy; 6.7 years in Romania; and 4.5 years 
in Spain. A delay in treatment because of COVID- 19 will increase liver mortality in all 
countries.
This is an open access article under the terms of the Creat ive Commo ns Attri bution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
© The Authors. Liver International published by John Wiley & Sons Ltd.
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1  | INTRODUTION
Hepatitis C virus (HCV) is a leading cause of liver- related morbid-
ity and mortality worldwide.1,2 The effect of antiviral therapy, 
in terms of the impact on clinical- related outcomes rather than 
virological efficacy, changes over time according to the epide-
miological profile of the disease, specific patient characteristics 
including fibrosis stage, and antiviral treatment efficacy.3- 7 These 
factors vary by country, meaning country- specific epidemiology of 
HCV infection, DAA treatment guidelines, and treatment access 
are expected to impact the burden of HCV- liver related outcomes 
following viral eradication. No clinical studies have assessed the 
impact of antiviral therapy on long- term morbidity and mortality, 
however, as it is unethical to maintain patients without therapy. 
Thus, only a modelling approach can address this issue and predict 
its impact on a population.5
In this study, we built country- specific models using real- life data 
of fibrosis stage, genotype distribution and treatment eligibility for 
England, Italy, Romania and Spain. These countries have varying ep-
idemiological patterns of infection, treatment eligibility and gross 
domestic product (GDP), thus providing a comprehensive evaluation 
on how treatment access in these different landscapes can influence 
their clinical and economic burden of HCV. Additionally, for these 
countries, the costs associated with each state of liver disease was 
available in the literature. Based on these considerations, we could 
evaluate the impact of HCV- related treatment policies on various 
economies throughout Europe.
The main objectives of this study were: (a) to estimate the num-
ber of HCV- related liver disease cases avoided according to the mod-
eled treatment scenarios in four European countries over a 20- year 
time horizon; (b) to assess, by country, the impact of antiviral therapy 
on the direct cost of HCV- related disease management; (c) to predict 
the neccessary time to recover the initial investment for treatment 
in each country; and (d) to evaluate how a treatment delay, because 
of the coronavirus disease 2019 (COVID- 19) pandemic, could impact 
disease burden outcomes.
2  | MATERIAL S AND METHODS
A country- specific Markov model was designed to estimate the clini-
cal and economic outcomes of expanded access to DAA therapy, 
considering the direct costs of HCV treatment in the European con-
text (England, Italy, Romania and Spain). The model inputs are shown 
in Tables 1 and 2.
2.1 | Model structure
A published Markov model (Supporting Information Figure A1) 
capturing multiple states of morbidity and mortality8- 10 and 
grounded in country- specific parameters was used to evaluate 
HCV disease progression and related costs for 1000 standardized 
treated patients over a 20 year time horizon. The model structure 
considers 13 disease states (fibrosis stages from F0 to F4, decom-
pensated cirrhosis (DC), hepatocellular carcinoma (HCC), first- year 
transplant and subsequent years transplant, sustained virological 
response (SVR) from F0 to F3, SVR from irreversible liver dam-
age (ILD), HCV- related death, and death from other causes, and 
41 transition probabilities.8- 10 Events constituting advanced liver 
disease, such as ILD or DC, were considered as cumulative events 
in the model and not mutually exclusive. Two different time pe-
riods, which covered the evolution of DAA eligibility criteria and 
prioritization of patients in each country, were considered. The 
first period (2015- 2016) captures the time of treatment prioriti-
zation according to the severity of fibrosis stage (F0- F4). In the 
Key points
• Despite the country- specific dynamics and natural his-
tory of hepatitis C virus (HCV) infection in Italy, Spain, 
Romania, and England, expanding access to treatment 
will lead to a positive return on investment and is cost 
saving in <10 years.
• Not treating or delaying treatment of infected individu-
als will result in higher disease burden and costs, which 
could be avoided with immediate screening, linkage to 
care, and treatment of all HCV infected individuals.
• As lockdown orders for coronavirus disease 2019 
(COVID- 19) begin to lift, providing direct acting antivi-
rals (DAAs) should remain a priority for public health of-
ficials in order to maintain HCV elimination efforts.
Conclusion: Direct- acting antivirals have significant clinical benefits and can bring substantial 
cost- savings over the next 20 years, reaching a Break- even point in a short period of time. 
When pursuing an exit strategy from strict lockdown measures for COVID- 19, providing DAAs 
should remain high on the list of priorities in order to maintain HCV elimination efforts.
K E Y W O R D S
break- even, DAAs, HCV elimination, hepatitis C infection
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TA B L E  1   Transition probabilities and efficacy of treatment (base- case, deterministic and probabilistic sensitivity analysis parameters)
Annual probability of disease progression Base- case
Parameter value  
used in the  
DSA [11]
Standard error 
included in  
the PSA Source
F0 to F1 0.117 0.113 0,010 [12]
F1 to F2 0.085 0.113 0,007 [12]
F2 to F3 0.120 0.113 0,010 [12]
F3 to F4 0.100 0.113 0,009 [13]
F4 to decompensated cirrhosis (DC) 0.030 0.041 0,003 [13]
F4 to HCC 0.050 0.021 0,004 [13]
Decompensated cirrhosis to HCC 0.100 0.014 0,009 [13]
Decompensated cirrhosis to transplant 0.110 0.031 0,009 [13]
HCC to transplant 0.200 0.031 0,017 [14]
SVR to HCCa  0.008 0.009 0,000 Assumption from [15]
SVR to transplanta  0.016 0.020 0,002 Assumption from [15]
Annual probability of progressing to death Base- case [11] Source
Decompensated cirrhosis to death (liver- related) 0.090 0.221 0,008 [15]
HCC to death (liver- related) 0.430 0.221 0,037 [14]
Transplant (procedure) to death (liver- related) 0.150 0.1715 0,013 [14]
Transplant (following years) to death (liver- related) 0.057 0.0353 0,005 [14]
Death from all other causes Italy [16]
2015- 2016 0.064 Average age 61.84
2017- 2019 0.062 Average age 60.17
Death from all other causes Romania Eurostat – Lifetable (2018) Table A1 [16]
2015- 2016 0.085 Average age 61.21
2017- 2019 0.085 Average age 61.21
Death from all other causes Spain Eurostat – Lifetable (2018) Table A1 [16]
2015- 2016 0.049 Average age 53.97
2017- 2019 0.049 Average age 53.97
Death from all other causes UK Eurostat – Lifetable (2018) Table A1 [16]
2015- 2016 0.051 Average age 52.67
2017- 2019 0.042 Average age 44.81
Efficacy of treatments— 2015 Base- case Min Max Source
F0- F3 to SVR (Genotype 1) 0.879 0.643 1.000 Appendix [17,18]
F4- DC to SVR (Genotype 1) 0.834 0.643 1.000
F0- F3 to SVR (Genotype 2) 0.742 0.500 1.000 Appendix [17,18]
F4- DC to SVR (Genotype 2) 0.742 0.500 1.000
F0- F3 to SVR (Genotype 3) 0.758 0.606 1.000 Appendix [17,18]
F4- DC to SVR (Genotype 3) 0.758 0.606 1.000
F0- F3 to SVR (Genotype 4 and more) 0.525 0.000 1.000 Assumed equal to F0- F3
F4- DC to SVR (Genotype 4 and more) 0.525 0.000 1.000 Appendix [17,18]
Efficacy of treatments— 2016 Base- case Min Max Source
F0- F3 to SVR (Genotype 1) 0.983 0.963 1.000 Appendix [17]
F4- DC to SVR (Genotype 1) 0.928 0.760 1.000 “
F0- F3 to SVR (Genotype 2) 0.960 0.920 1.000 “
(Continues)
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the second time period (2017- 2019), all countries except Romania 
relaxed treatment restrictions, such that patients in earlier stages 
of fibrosis were eligible for treatment.
2.2 | Transition probabilities
The probabilities of progressing through the various stages of disease 
were based on the results of a literature review (Table 1). Throughout 
annual cycles, patients could remain in their current liver disease 
stage or progress to a worse state according to the natural history 
of the disease. This progression can be stopped or slowed down by 
treatment. The DAA efficacy was expressed in terms of probability 
to reach an SVR state. If patients were cured in stages F0- F3 (they 
move to the SVR state), the model assumed that liver damage was re-
versed. Patients achieving an SVR in stages F4, DC and HCC were no 
longer infectious, but they could incur additional liver damage (F4 and 
DC could progress to HCC, or need a LT). The probabilities of mov-
ing from SVR- ILD to HCC or LT were weighted for the percentage of 
patients with compensated cirrhosis, DC and HCC. In the model, pa-
tients could die because of HCV- related diseases only if they were in 
the DC, HCC, LT (procedure) or LT (following years) disease stages.11-
 17 As a certain proportion of patients with F3 fibrosis may in fact 
have undiagnosed F4 liver fibrosis (PITER data, not shown), 10% of 
patients that achieved an SVR in F3 were progressed in the model ac-
cording to the transition probabilities of achieving SVR in stage F4.18
All transition probabilities are adjusted for competing probabil-
ities of death from other causes according to the official data from 
each country (Supporting Information Table A1).16 For the HCC 
state, the probability of death because of HCV and the probability of 
transplant were assumed to be independent.
2.3 | Epidemiological and clinical parameters
The model simulates a cohort of 1000 standardized treated patients 
according to real- life fibrosis stage and genotype distribution data 
for England, Italy, Romania and Spain.19- 23 Fibrosis stage by age and 
genotype distribution of treated patients by year for each of the 
countries included in the study were collected. The fibrosis distri-
bution of treated patients for each country is reported in Figure 1, 
while the genotype distribution for each country during the two 
time periods evaluated is shown in Table A2 of the Supporting 
Information. According to these data, we simulated treatment in 
a cohort of standardized patients for each year evaluated, specifi-
cally years 2015- 2016 and another cohort of standardized patients 
treated during 2017- 1019. Avoided clinical events after therapy, po-
tential cost reductions and return on investment of antiviral therapy 
were forecasted over a 20 year time horizon for both cohorts and 
outcomes were compared to a cohort of non- treated patients.
2.4 | Treatment efficacy
The efficacy of second- generation DAA regimens used in each pe-
riod was stratified by genotype distribution and the presence or ab-
sence of cirrhosis (F0- F4, DC or HCC), as summarized in Table 1 and 
Tables A3- A5 in the Supporting Information3,17,18.
Efficacy of treatments— 2016 Base- case Min Max Source
F4- DC to SVR (Genotype 2) 0.952 0.710 1.000 “
F0- F3 to SVR (Genotype 3) 0.960 0.940 1.000 “
F4- DC to SVR (Genotype 3) 0.860 0.710 1.000 “
F0- F3 to SVR (Genotype 4 and more) 0.963 0.940 1.000 “
F4- DC to SVR (Genotype 4 and more) 0.943 0.800 1.000 “
Efficacy of treatments— 2017- 2019 Base- case Min Max Source
F0- F3 to SVR (Genotype 1) 0.980 0.784 1.000 Appendix [17]
F4- DC to SVR (Genotype 1) 0.931 0.745 1.000 “
F0- F3 to SVR (Genotype 2) 0.980 0.784 1.000 “
F4- DC to SVR (Genotype 2) 0.970 0.776 1.000 “
F0- F3 to SVR (Genotype 3) 0.950 0.760 1.000 “
F4- DC to SVR (Genotype 3) 0.884 0.707 1.000 “
F0- F3 to SVR (Genotype 4 and more) 0.970 0.776 1.000 “
F4- DC to SVR (Genotype 4 and more) 0.961 0.769 1.000 “
Abbreviations: DC, decompensated cirrhosis; DSA, deterministic sensitivty analysis; HCC, hepatocellular carcinoma; ILD, irreversible liver damage; 
PSA, probabilistic sensitivity analysi; SVR, sustained virological response.
aOnly for SVR to ILD. 
TA B L E  1   (Continued)
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TA B L E  2   Cost parameters (base- case, deterministic and probabilistic sensitivity analysis parameters)
Cost of treatment
England
Base- case Min Max
Standard error 
included in the PSA Source
Treatment 2015 € 30,000.00 € 8,000.00 € 30,000.00 € 6,000.00 Assumption by local 
expert
Treatment 2016 € 22,000.00 € 8,000.00 € 30,000.00 € 4,400.00 “
Treatment 2017 € 18,000.00 € 8,000.00 € 30,000.00 € 3,600.00 “
Treatment 2018 € 9,000.00 € 8,000.00 € 30,000.00 € 1,800.00 “
Treatment 2019 € 8,000.00 € 8,000.00 € 30,000.00 € 1,600.00
Other direct medical costs Base- case Min Max SE Source
F0 € 202 € 182 € 223 € 38 Appendix [24]
F1 € 202 € 182 € 223 € 38 “
F2 € 1,051 € 946 € 1,156 € 326 “
F3 € 1,051 € 946 € 1,156 € 47 “
F4 € 1,668 € 1,502 € 1,835 € 135 “
Decompensated Cirrhosis (DC) € 13,371 € 12,034 € 14,708 € 1.932 “
HCC € 11,915 € 10,723 € 13,106 € 3.470 “
Transplant (procedure) € 40,068 € 36,061 € 44,075 € 19.241 “
Transplant (following years) € 3,214 € 2,892 € 3,535 € 650 “
SVR € 715 € 644 € 787 € 307 “
SVR to ILD statesa  € 1,668 € 1,502 € 1,835 € 350 “
Cost of treatment
Italy
Base- case Min Max SE Source
Treatment 2015 € 25,000.00 € 5,000.00 € 25,000.00 € 5,000.00 Assumption by local 
experts
Treatment 2016 € 15,000.00 € 5,000.00 € 25,000.00 € 3,000.00 “
Treatment 2017 € 9,000.00 € 5,000.00 € 25,000.00 € 1,800.00 “
Treatment 2018 € 6,000.00 € 5,000.00 € 25,000.00 € 1,200.00 — 
Treatment 2019 € 5,000.00 € 5,000.00 € 25,000.00 € 1,000.00
Other direct medical costs Base- case Min Max SE Source
F0 € 234 € 176 € 292 € 25 [8- 10,17]
F1 € 234 € 176 € 292 € 25 “
F2 € 234 € 176 € 292 € 25 “
F3 € 617 € 292 € 942 € 139 “
F4 € 876 € 397 € 1,354 € 205 “
Decompensated Cirrhosis (DC) € 6,627 € 4,385 € 8,868 € 962 “
HCC € 12,896 € 5,792 € 20,000 € 3.049 “
Transplant (procedure) € 73,774 € 62,648 € 84,900 € 4.775 “
Transplant (following years) € 2,365 € 0 € 4,729 € 1.015 “
SVR € 0 € 0 € 0 € 0 “
SVR to ILD statesa  € 1,440 € 397 € 2,483 € 448 Assumption from [25]
Cost of treatment
Romania
Base- case Min b Max b SE Source
Treatment 2015 € 15,000.00 € 5,000.00 € 15,000.00 € 3,000.00 Assumption by local 
expert
(Continues)
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2.5 | Scenarios
The model simulates two different scenarios considering 1000 
standardized patients over a 20- year time horizon:
1. No treatment (base case scenario) : patients in disease stages 
F0- F4 follow the natural history of HCV without any therapy;
2. Treatment scenarios: A cohort of 1000 standardized patients were 
treated in specific years according country specific genotype and 
Cost of treatment
Romania
Base- case Min b Max b SE Source
Treatment 2016 € 12,000.00 € 5,000.00 € 15,000.00 € 3,000.00 “
Treatment 2017 € 6,000.00 € 5,000.00 € 15,000.00 € 2,400.00 “
Treatment 2018 € 6,000.00 € 5,000.00 € 15,000.00 € 1,200.00 “
Treatment 2019 € 5,000.00 € 5,000.00 € 15,000.00 € 1,000.00
Other direct medical costs Base- case Min Max SE Source
F0 € 77 € 69 € 85 € 92 [26]
F1 € 77 € 69 € 85 € 92 “
F2 € 77 € 69 € 85 € 92 “
F3 € 77 € 69 € 85 € 371 “
F4 € 582 € 524 € 640 € 331 “
Decompensated Cirrhosis (DC) € 930 € 837 € 1,023 € 3.407 “
HCC € 592 € 533 € 651 € 8.330 “
Transplant (procedure) € 56,699 € 51,029 € 62,369 € 12.103 “
Transplant (following years) € 6,892 € 6,203 € 7,581 € 928 “
SVR € 0 € 0 € 0 € 0 “
SVR from ILD states a  € 735 € 662 € 809 € 750 “
Cost of treatment
Spain
Base- case Min Max SE Source
Treatment 2015 € 25,000.00 € 5,000.00 € 25,000.00 € 5,000.00 Assumption by local 
expert
Treatment 2016 € 15,000.00 € 5,000.00 € 25,000.00 € 3,000.00 “
Treatment 2017 € 9,000.00 € 5,000.00 € 25,000.00 € 1,800.00 “
Treatment 2018 € 6,730.00 € 5,000.00 € 25,000.00 € 1,346.00 “
Treatment 2019 € 5,000.00 € 5,000.00 € 25,000.00 € 1,000.00 “
Other direct medical costs Base- case Min Max SE Source
F0 € 306 € 306 € 306 € 6 [27,28]
F1 € 306 € 306 € 306 € 6 “
F2 € 306 € 306 € 306 € 6 “
F3 € 306 € 306 € 306 € 273 “
F4 € 556 € 556 € 556 € 342 “
Decompensated Cirrhosis (DC) € 2,266 € 2,266 € 2,266 € 2.834 “
HCC € 8,630 € 8,630 € 8,630 € 4.880 “
Transplant (procedure) € 121,707 € 121,707 € 121,707 € 15.797 “
Transplant (following years) € 35,575 € 35,575 € 35,575 € 13.238 “
SVR € 6 € 6 € 6 € 2 [29]
SVR to ILD states a  € 162 € 162 € 162 € 996 “
Abbreviations: DC, decompensated cirrhosis; HCC, hepatocellular carcinoma; ILD, irreversible liver damage; PSA, probabilistic sensitivity analysi; 
SVR, sustained virological response.
aWeighted average of states F4, DC and HCC (HCC costs are assumed equal to those of DC). 
TA B L E  2   (Continued)
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fibrosis stage distribution, and followed over a 20 year time ho-
rizon after achieving SVR. This scenario was conducted for two 
cohorts of standardized patients. Scenario 2015- 2016 captured 
patients treated during 2015- 2016 according to the specific 
country's prioritized eligibility criteria and Scenario 2017- 2019, 
which captured patients treated during 2017- 2019 with no treat-
ment restrictions or restrictions according to the eligibility cri-
teria in Romania. The outcomes (clinical and economic) of both 
F I G U R E  1   Proportion of patients by disease stage in England, Italy, Romania and Spain in 2015- 2016 and 2017- 2019. A, Period 2015- 
2016; (B) Period 2017- 2019. F0- F2: liver fibrosis stage F0- F2; F3: liver fibrosis stage F3; F4: liver fibrosis stage F4 (liver cirrhosis); DC: 
Decompensated Cirrhosis; HCC: Hepatocellular Carcinoma
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treatment scenarios were compared to the base case (no treat-
ment) scenario.
Economic results were reported as the absolute difference be-
tween the estimated cost of the 2015- 2016 and 2017- 2019 sce-
narios to the “no treatment” scenario. The Break- even analysis 
calculates the Break- even Point in Time (BPT), which considers the 
time (in years) needed to minimize this difference to zero.
2.6 | Economic parameters and analysis
Direct healthcare costs were those associated with the manage-
ment of HCV- related diseases, (including related outpatient visits, 
biochemical analyses, instrumental procedures, management and 
treatment of DC, HCC, and liver transplantation) along with costs of 
DAAs.10 The costs considered in the model estimate an average cost 
per health state considering treated/managed and not treated/not 
managed patients. All of the cost parameters considered for each 
country come from the cost- effectiveness analysis that applies these 
costs with the same methodology applied in our case and are sum-
marized in Table A6 of the Supporting Information. The average and 
range of costs (MINIMUM– MAXIMUM) of HCV- related liver dis-
ease were derived from the literature (Table 2).10,17,24,29 The average 
treatment cost of DAAs was estimated based on expert opinion and 
non- official sources.
The associated per- patient cost by disease stage post- SVR was 
assumed to be null, presuming a state of full health after SVR for the 
patient until F3 fibrosis stage (Table 2 and Supporting Information 
Figure A1). The associated per- patient cost by disease stage post- 
SVR from ILD remained associated to the costs of ILD prior to ther-
apy, independently of the achievement of SVR (Table 2) or the costs 
of other related events during disease progression. The annual costs 
saved were calculated as the estimated costs accrued of the no 
treatment scenario (base case) minus the estimated accrued costs of 
the two treatment scenarios (2015- 2016 and 2017- 2019 scenarios). 
Costs were expressed in Euros and were discounted at a rate of 3% 
annually.
2.7 | Sensitivity analysis
To estimate the uncertainty of the economic results, probabilistic 
sensitivity analysis (PSA) and deterministic sensitivity analysis (DSA) 
were performed. The probabilistic distribution choice for cost was 
made by applying a gamma distribution and for epidemiological pa-
rameters, a beta distribution.30 Tables 1 and 2 report the standard 
error considered for the probabilistic distribution considering an 
arbitrary variation of 20%. Furthermore, 5000 Monte Carlo simu-
lations were performed to provide 95% confidence intervals (95% 
CIs) for case and cost reduction at 20 years, Break- even point, and 
case reduction at the Break- even point. In the DSA, each sensible 
parameter of the model was subject to a variation derived from the 
literature (transition probabilities) or from an arbitrary variation30 as 
reported in Tables 1 and 2. The model results derived from each vari-
ation were compared to the value of the base case and represented 
by a tornado diagram.
2.8 | Delayed treatment scenario
A delayed treatment scenario because of the COVID- 19 pandemic 
was developed to estimate the incremental cases associated with 
the subsequent scenario:
1. Base- case 2020: all patients were treated during the first year 
and followed for 5 years;
2. Delay to treatment scenario: a delay in treatment for 3- 12 months 
was considered as a percentage of patients who may have their 
treatment postponed to the subsequent year.
The model was populated with the 2019 fibrosis distribution for 
each country, except for Spain where the fibrosis stage and geno-
type distributions considered in 2019 and 2020 are assumed the 
same as those reported in 2018 (Supporting Information Table A7). 
The liver related outcomes (number of irreversible liver damage (ILD) 
and number of liver- related deaths standardized for a delay of treat-
ment of 1000 patients over a period of 5 years were evaluated in 
the four countries. Preliminary estimates were reported for Italy and 
England in a previous Correspondence31
3  | RESULTS
3.1 | Characteristics of treated patients by country, 
according to fibrosis stage
As the four European countries have different treatment eligibility cri-
teria, the distribution of fibrosis stages among treated patients varied 
significantly. Specifically, from 2015- 2016, 60% of patients in England, 
70% of Italian patients, 94% of Romanian patients and 47% of Spanish 
patients had fibrosis stage F4 or more advanced decompensated cir-
rhosis or hepatocellular carcinoma. From 2017- 2019, there was a 
30%- 60% increase in the number of F0- F2 patients treated in England, 
Spain and Italy, but only a 25% increase in Romania. (Figure 1).
3.2 | Evaluation of clinical outcomes from 2015- 
2035
By expanding access to DAA therapies in 2017- 2019, the model es-
timated a decrease in end- stage liver disease in all countries. There 
would be 640 fewer events of advanced liver disease in England, 
626 fewer events in Italy, 643 fewer events in Spain and 739 fewer 
events in Romania over the next 20 years. More cases of ILD are 
avoided in 2015- 2016 as compared to 2017- 2019 (Table 3).
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3.3 | Evaluation of costs and return on investment 
from 2015- 2035
The potential reduction in clinical events over the next 20 years 
for patients treated between 2015- 2019 is cost saving in all coun-
tries. The overall savings for 1000 standardized treated patients 
over 20 years are estimated to be: about € 81 million in England, 
€ 63 million in Italy, € 45 million in Romania and € 275 million in 
Spain.
In all countries, it would take less than 10 years to reach a Break- 
even point (Table 3). Overall, it would take England the longest 
amount of time to reach a Break- even point (6.5 years), while Spain 
would see the return on investment in <5 years (Figure 2).
The costs avoided and Break- even estimations over the next 
20 years based on the DSA analysis are reported in Figure 3. Detailed 
results of DSA are reported in the Tables A5 and A6 and in Tables A8 
and A9 of the Supporting Information. Transition probabilities had 
the highest impact on both the number of years needed until the 
Break- even point and the total costs saved over the 20- year time 
horizon for Italy, Spain, and Romania (25%, 59%, and 94%, respec-
tively). For England, the variation of treatment cost led to a higher 
level of variability (−19% in the minimum scenario).
Considering the confidence intervals around the base case val-
ues (Table 3), which were estimated in the PSA analysis, the Break- 
even points are similar to the base case values in all countries except 
Romania. In Romania, the max variation is almost double the time 
estimated in base case analysis. Higher variation is reported during 
the first treatment period (prioritized) vs the second treatment 
period (universal). The Break- even point would take between 4.5 
and 8.9 years in England, 3.4 years and 7.8 years in Italy, 3.0 and 
12.0 years in Romania, and 3.4 and 5.8 years in Spain.
3.4 | Delayed treatment because of COVID- 19
As shown in Figure 4, there will be a progressive increase in HCV 
disease- related outcomes because of the delay in treatment caused 
by COVID- 19. Generally, there will be an increase in the number of 
estimated irreversibile liver disease cases for all countries. Romania 
would experience the largest increase in disease burden. Liver- 
related deaths would increase at a slower rate compared to the in-
crease in disease burden for all countries except Italy. In Italy, the 
additional number of liver related mortalities would increase at the 
same rate as the additional number of irreversibile liver disease 
cases.
4  | DISCUSSION
The characteristics of HCV infection vary among countries because 
of different epidemic waves and modes of transmission. In Italy and 
Romania, an intensive epidemic wave occurred during the 1950s 
and 1960s, mainly associated with poor hygiene during invasive 
procedures, whereas in the other countries of this study, the most 
intensive epidemic waves occurred after the 1980s, mainly related 
to transfusions and intravenous drug use.32- 36 Thus, considering 
these diverse waves and peak infection rates, differences are ex-
pected in the distribution of fibrosis stage cases and the impact of 
treatment on the natural history of infection.
The varying distribution of treated patients by disease stage 
in this study reflected the country- specific treatment eligibility 
policies. In the 2015- 2016 time period, Italy and Romania were 
estimated to avoid the largest number of end- stage liver disease 
events. Data have suggested that once cirrhosis is established, 
there is a high risk of developing HCC or hepatic decompensation 
and, following an episode of decompensation, there is a high risk 
of death.37- 40 This explains why countries which prioritized treat-
ment of advanced fibrosis in 2015- 2016 (Italy and Romania) are es-
timated to avoid more late stage liver disease events compared to 
those with fewer treatment restrictions (England, Italy and Spain) 
in 2017- 2019.
In 2017- 2019, when fibrosis restrictions were removed in all 
countries except Romania, the time to return on investment was 
smaller compared to 2015- 2016. The different cost savings and con-
secutively the time to return of investment reflect, in part, the dif-
ferent costs of treating different disease stages in the four countries. 
Generally, the time to return on investment is related to two factors: 
cost of DAAs and liver disease costs. Specifically, the cost of DAAs 
administered to patients in 2015- 2016 was higher than that adminis-
tered to patients in 2017- 2019, suggesting that the return on invest-
ment decreased over time was also because of the decreasing price 
of treatment. In a previous study in Italy in which patients treated 
in 2015 were evaluated using the same methodology, costs saved 
on avoided clinical events did not translate into a positive return on 
investment.10 This was because of the higher price of DAAs and also 
by treating patients with cirrhosis, which still accrued higher costs 
despite viral eradication.41
Generally, these estimations could vary given different progres-
sion rates. However, as seen by the sensitivity analysis results, a re-
turn of investment is expected within 10 years in all countries except 
Romania. If Romania expands DAA eligibility criteria, similar trends 
in costs saved and return on investment as seen in other countries, 
would be observed.
As COVID- 19 has become a global pandemic, we considered 
the impact that the disease may having on delaying access to DAA 
therapy. Despite major differences in HCV epidemiology and dis-
ease burden among the evaluated countries, the delayed treatment 
scenario generates comparable liver related mortality in the four 
countries evaluated. Over time, severe clinical outcomes because of 
delayed treatment will be evident in England, Spain and Romania, 
which will however result in less mortality than seen in Italy. In these 
three countries, while progressive liver disease will be evident across 
the next 5 years if treatment is delayed, the HCV infected popula-
tion, as seen by the treatment data, is more likely to be in earlier 
stages of disease. On the contrary, in Italy, the liver morbidity is gen-
erally equal to the liver mortality because among individuals who 
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F I G U R E  2   Differences in costs and the Break- even Point in Time (BPT) by treatment scenario in England, Italy, Romania and Spain over 
a 20- year time horizon. A, Period 2015- 2016; (B) Period 2015- 2016; (C) Overall Period 2015- 2019. The differences in costs are compared vs 
the No treatment scenario. The BPT is the point where where the each cost difference line crosses the abscissa (X axis)
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are awaiting treatment and those who are expected to be diagnosed 
through screening in 2020- 2021, more than 100,000 individuals are 
estimated to have cirrhosis.42,43 Hence, deferring DAA treatment for 
an additional six months in Italy would, over the next 5 years, lead to 
an additional 500 HCV- related deaths. All of these deaths would be 
avoidable if testing and treatment were not deferred.31
F I G U R E  3   Deterministic Sensitivity Analysis assessing the impact of the parameters’ variation on the Break- even estimations and total 
Costs avoided. A, England Break- even estimations; (B) England costs avoided; (C) Italy Break- even estimations; (D) Italy costs avoided; (E) 
Romania Break- even estimations; (F) Romania costs avoided; (G) Spain Break- even estimations; (S) Spain costs avoided
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If we accept the temporary need to reduce HCV elimination 
efforts because of the COVID- 19 pandemic, we should at least 
preserve the availability of immediate treatment for patients with 
advanced fibrosis or cirrhosis. Even if this may reduce severe disease 
outcomes, it will be only partially effective, as patients with early- 
stage fibrosis may further progress and undiagnosed HCV patients 
with severe fibrosis will not be screened and treated in time. We sug-
gest that in all countries worldwide, whatever the residual burden 
of untreated HCV infection, when pursuing an exit strategy from 
strict lockdown measures for COVID- 19, providing DAA treatments 
should remain high on the list of priorities in order to support HCV 
elimination strategies.31
Limitations to this modelling study exist. Firstly, several inputs 
of the model are based on literature data and applied to all coun-
tries. Drug costs were provided by country experts and are not 
official data. Thus, inputs may be over or underestimated for each 
country. However, despite the limited data available from the liter-
ature, particularly regarding the specific natural history of disease 
for each country, this approach considers all available evidence and 
represents a proxy of what decision- makers could expect from their 
public health decisions. Second, antiviral treatment is considered as 
the disease cure if an SVR is reached. The SVR, however, primar-
ily depends on the fibrosis stage at treatment onset as well as on 
host- related and concomitant risk factors.3 Moreover, this modelling 
approach applied the same transition probabilities to the different 
pre- treatment fibrosis stages, which may bias the outcomes. The 
transition probabilities used in this study are widely used in the lit-
erature, however, liver fibrosis progression is not a linear process. 
The progression probabilities could vary by country based on host 
and environmental factors, such as alcohol consumption, metabolic 
syndrome or comorbidities. These factors are equally distributed in 
different countries and may affect treatment outcomes and costs. 
In order to limit the effect of these uncertainties (and as commonly 
done in other modelling studies on the natural history of HCV in-
fection), a sensitivity analysis was conducted, evaluating the impact 
of varying transition probabilities. Secondly, this analysis does not 
address how individuals will be identified for treatment, which is 
also cost intensive. A recent analysis determined that an expanded 
HCV screening stategy was cost effective in Italy, but the scenar-
ios reported here analyse only the return on investment of antiviral 
therapy and does not consider screening costs.42 Thus, only efficacy 
and not effectiveness results in economic terms are reported in this 
analysis. Additional screening analyses in the three other countries 
included in this paper are warranted. Thirdly, this analysis was not 
focused on treatment as prevention, nor on the impact of reinfec-
tion of treated patients, particularly among people who inject drugs 
(PWID). Given the lack of available literature on the potential re-
infection of treated individulas for each of the countries analysed, 
it was not possible to evaluate the role of new infections and rein-
fections on the return on investment of treated patients. This point 
should be considered in future studies on high risk populations, in 
which the probability of reinfection is high. In this particular study, 
data are based on the overall treated population and the impact of 
reinfection would consider only a portion of treated patients in each 
country.
In conclusion, the results of this study show that despite the 
country- specific dynamics and natural history of HCV infection in 
Italy, Spain, Romania and England, there will be a positive return on 
F I G U R E  4   Additional cases of Irreversible Liver Disease and HCV- related deaths because of treatment delay by COVID- 19 pandemic. 
Estimations for 1,000 patients at 5 years of follow- up in England (A), Italy (B), Romania (C), Spain (D)
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investment and expanding access to treatment is cost saving in less 
than 10 years in the countries analysed. Universal access to therapies 
in all infected individuals will result in stronger economic returns and 
less disease burden. It should be noted though, as depicted in the de-
layed treatment scenario, that not treating or delaying treatment of 
infected individuals will result in higher disease burden and consecu-
tively higher costs for the NHS. Policy makers could consider these ef-
forts when determining the most cost- effective methods for managing 
HCV infection across Europe. As lockdown measures for COVID- 19 
begin to lift, providing DAAs should remain high on the list of priorities 
for public health officials in order to maintain HCV elimination efforts.
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